Beyond the Filler Paradigm
The word "filler" has dominated the injectable aesthetics vocabulary for two decades, and in doing so has subtly misframed the clinical conversation. Filler implies addition — a passive occupying of space to restore volume. It does not imply biology. It does not imply cellular activation.
Biostimulants are a different category of injectable. They do not fill a space. They instruct the biology of the dermis and subcutaneous tissue to rebuild one. The three clinically established agents — poly-L-lactic acid (PLLA), calcium hydroxylapatite (CaHA), and polycaprolactone (PCL) — share this fundamental philosophy but differ substantially in their mechanisms, timelines, and ideal clinical applications.
Poly-L-Lactic Acid (PLLA): The Macrophage-Mediated Collagen Architect
PLLA is a synthetic, biodegradable alpha-hydroxy acid polymer. Its biostimulatory mechanism is heavily dependent on macrophage-mediated inflammatory signaling. PLLA microspheres injected into the dermis are recognized as foreign by resident macrophages, which phagocytose the smaller particles and encapsulate the larger ones, differentiating into M2-polarized giant cells.
A 2025 multicenter RCT involving 331 subjects found that PLLA achieved 90.57% improvement in midfacial volume at 12 months, outperforming HA fillers. Histological analysis confirmed collagen formation persisting at 25 months.
Calcium Hydroxylapatite (CaHA): Mechanotransduction and the Dual-Phase Advantage
CaHA (Radiesse) consists of 30% calcium hydroxylapatite microspheres suspended in a carboxymethylcellulose gel carrier. Its mechanism is fundamentally different from PLLA's. CaHA activates fibroblasts through direct mechanotransduction rather than through diffusible inflammatory mediators.
The distinctive clinical property is the simultaneous dual-phase effect: the gel carrier provides immediate volumization while CaHA microspheres stimulate neocollagenesis over 6–12 months. Hyperdiluted CaHA (1:4 dilution) has emerged as the preferred approach for skin tightening without structural volumization.
Polycaprolactone (PCL): The Long-Duration Scaffold
PCL (Ellans) is the most recently established biostimulant with the longest potential duration of action. PCL degrades by slow hydrolysis of ester bonds, with the Ellans product range offering durations from approximately 1 year to 4 years.
PCL microspheres at 25–50 microns are too large to be phagocytosed by macrophages. They instead become encapsulated in a fibrous tissue reaction where fibroblasts deposit new collagen.
The Decision Framework: Matching Mechanism to Patient Biology
PLLA is preferred for progressive, diffuse volumetric restoration over 3–6 months when the patient commits to 2–3 sessions. Duration of biostimulatory activity is documented at 25 months.
CaHA is preferred when the patient requires both immediate structural correction and sustained biostimulation. The dual-phase mechanism is its distinctive advantage.
PCL is preferred when the patient prioritizes longevity above all other considerations, with adjustable duration from 1 to 4 years.
A 2025 systematic review confirmed that PLLA induces collagen through M2 macrophage polarization; CaHA through direct fibroblast contact-mediated mechanotransduction; and PCL through combined scaffold-mediated mechanotransduction. These are three distinct biological pathways, not three versions of the same intervention.
The right biostimulant is the one that matches your biology, not the clinic's preference.